ea0090ep801 | Pituitary and Neuroendocrinology | ECE2023
Badiu Corin
, Mariash Cary N.
, Kautzky-Willer Alexandra
, Shlomai Gadi
, Aresta Carmen
, Pivonello Rosario
, Dischinger Ulrich
, Bancos Irina
, Dobri Georgiana
, Hamrahian Amir
, Auchus Richard
, Feelders Richard
, Recasens Monica
, Chmiel-Perzynska Iwona
, Pearson Emily
, Moraitis Andreas G.
, Araque Katherine
Cushing syndrome (CS) is a chronic and debilitating condition with high morbidity and mortality. Development of novel, safe, and effective pharmacologic therapies with improved risk-benefit profiles would enrich treatment options for patients. Relacorilant is a selective glucocorticoid receptor (GR) modulator that competitively antagonizes cortisol activity and, unlike the FDA-approved GR antagonist mifepristone, does not bind to the progesterone receptor. In a phase 2 study i...